



1 mM
100 µM
10 mg/kg
3 mg/kg
1 mg/kg
Time (hr)
0
60
120
180
240
300
360
420
480
540
600
1
10
100
1000
1E+04
Eltrombopag Concentration (ug/mL)

FIG. 1


A
Cerebellum
B
Kidney
C
Heart
D
Muscle
CoQ10 Conc. (ug/mg protein)
Oral Vehicle
IP Vehicle
Oral CoQ10 10 mg/kg BID
Oral BPM31510 10 mg/kg BID
Oral CoQ10 50 mg/kg BID
Oral BPM31510 50 mg/kg BID

FIGS. 2A-2D


B
Absolute ox-CoQ10 Concentration
(pg/1M cells)
0.04
0.03
0.02
0.01
0.00
Control
PAβA 1mM
PAβA 1mM +EPA:DHA 15:10 0.2μM
PAβA 1mM +EPA:DHA 15:10 1.0μM
PAβA 1mM +EPA:DHA 15:10 2.5μM
****
****
****
A
CoQ10 Concentration (pg/1M cells)
0.020
0.015
0.010
0.005
0.000
Vehicle
1 mM PAβA
****

FIGS. 3A-3B



***
ns
ns
*
1500
1000
500
0
ATP (nM)
Vehicle
1mM PABA
1mM PABA+ 0.2µM BPM31510
1mM PABA+ 1µM BPM31510
1mM PABA+ 2.5 µM BPM31510

FIG. 4



**
**
*
**
200
150
100
50
0
Geometric MFI
(normalized to Vehicle)
1 mM PABA
-
+
+
+
+
BPM31510 (μM)
0
0
0.2
1
2.5

FIG. 5



ATP Concentration
(nmol/mg protein)
25
20
15
10
5
0
**
*
**
Untreated
BPM31510
Untreated
BPM31510
Untreated
BPM31510
Control
PDSS2
COQ2

FIG. 6



24 Hours
1 Week
Ox CoQ10 (µg/mg protein)
15
10
5
1.0
0.5
0.0
100-fold
7-fold
145-fold
7-fold
Control
CoQ2
Ox CoQ10 (µg/mg protein)
100
50
3
2
1
0
640-fold
450-fold
14-fold
Cells Died
Control
CoQ2
Untreated
CoQ10 (5µM)
BPM31510 (5µM)

FIG. 7



Gastrocnemius CoQ10
Brain CoQ10
Heart CoQ10
Kidney CoQ10
CoQ10-ox Concentration (µg/mg protein)
Vehicle
BPM31510
WT
CoQ4-KI
ns
*
**
***
****
+730%
+1,302%
+48%
+102%
+124%
+42%
+732%
+432%
+54%
+267%
+226%
P > 0.05
P ≤ 0.05
P ≤ 0.01
P ≤ 0.001
P ≤ 0.0001

FIG. 8




CoQ10 Spatial Distribution from Heart
Not treated
BPM31510 treated
WT M8
WT F4
WT F6
WT F7
KI M2
KI M5
KI F9
KI M1
WT F2
WT M3
KI F1
KI M4
WT M1
KI F2
KI M6
KI F4
KI M7
KI F5
H & E
CoQ
CoQ9
Hema B
Composite
CoQ9 Hema B
Not treated
BPM31510 treated
WT
KI

FIG. 9


ROI 1
ROI 2
Intensity (a.u.)
WT
KI
Not treated
BPM31510 treated
Coq9
Coq10


ROI 1- Vascular enriched
ROI 2- Tissue

FIG. 10



CoQ10 Spatial Distribution from Brain
Not treated
BPM31510 treated
WT M5
WT F4
WT F5
WT L7
KI L4
KI M5
KI F5
KI M7
KI F7
KI L7
H & E
CoQ
CoQ9
Heme B
Composite
CoQ10 CoQ9 Heme B
WT
KI
Not treated
BPM31510 treated

FIG. 11



CoQ Spatial Distribution from Cerebellum
CoQ10
CoQ9
Intensity (a.u.)
0
20
40
60
80
100
WT
Ki
WT
Ki
Not treated
BPM31510 treated
ns
*
**
***

FIG. 12



CoQ Spatial Distribution from Seg. ROI
ROI 1-white enriched
ROI 2- grey enriched
ROI 3- vascular enriched
Further classification
CoQ9
CoQ10
ROI 1
ROI 2
ROI 3
Intensity (a.u.)
Vehicle
BPM31510
WT
Cox4i-KI

FIG. 13



CoQ10 Spatial Distribution from Kidney
Not treated
BPM31510 treated
WT M8
WT F4
WT F6
WT F7
K M4
K M5
K F8
K F9
WT M3
WT F2
K M1
WT F5
K F7
H & E
CoQ10
CoQ9
Heme B
Composite
CoQ9/Heme B
Not treated
WT
Ki
BPM31510 treated
WT
Ki

FIG. 14



CoQ Spatial Distribution from Seg. ROI
CoQ10
CoQ9
ROI 1- Outer cortex
ROI 2- Inner cortex
ROI 3- Medulla
ROI 4- Pelvis
ROI 5- vascular
ROI 1 Outer cortex
ROI 2 Inner cortex
ROI 3 Medulla
ROI 4 Pelvis
ROI 5 Vascular
Intensity (a.u.)
Vehicle
BPM31510
WT
Coq4-/-

FIG. 15



COQ01 (m,17)
COQ02 (f,8)
SARA [0-40 pts]
20
15
10
5
0
ø12.5
ø11
10.5
9.5
BL1
BL2
wk4
wk8
Visit
SARA: Minimal Important change is ≥1

FIG. 16



COQ01 (m,17)
COQ02 (f,8)
9-Hole Peg-Test [sec]
dominant hand
70
60
50
40
30
BL1
BL2
wk4
wk8
Visit
ø56
ø47
49
40

FIG. 17



Activities of Daily Living
(FARS-ADL [0-32 pts])
20
15
10
5
0
BL1
BL2
wk4
wk8
Visit
Patient Global Impression
of Change (Iterative)
3
2
1
0
-1
-2
-3
COQ01 (m,17)
COQ02 (f,8)
+3 very much improved
+2 much improved
+1 minimally improved
0 no change
-1 minimally worse
-2 much worse
-3 very much worse

FIG. 18



Caregiver Global Impression
of Change (Iterative)
3
2
1
0
-1
-2
-3
BL1
BL2
wk4
wk8
Visit
+3 very much improved
+2 much improved
+1 minimally improved
0 no change
-1 minimally worse
-2 much worse
-3 very much worse

FIG. 19



+3 very much improved
+2 much improved
+1 minimally improved
0 no change
-1 minimally worse
-2 much worse
-3 very much worse
Gait and Balance
PGI/CaGI-C (iterative)
Dexterity
PGI/CaGI-C (iterative)
Speech
PGI/CaGI-C (iterative)
Cognition
PGI/CaGI-C (iterative)
3
2
1
0
-1
-2
-3
BL1
BL2
wk4
wk8
Visit

FIG. 20



Goal 1: Writing speed
+4 = 5 minutes (normal)
+3 = < 8 minutes
+2 = <10 minutes
+1 = >10 minutes
0 = 10-15 minutes
-1 = >1 minutes
Goal 2: Walking capacity
+4 = >30 minutes (normal)
+3 = >15 minutes
+2 = >10 minutes
+1 = 5-10 minutes
0 = 3-5 minutes
-1 = <3 minutes
Goal Attainment Scale
4
3
2
1
0
-1
BL1
BL2
wk4
wk8
Visit
Goal 1: Writing speed
+4 = ~20 minutes
+3 = ~30 minutes
+2 = ~40 minutes
+1 = ~50 minutes
0 = 60 minutes
-1 = >60 minutes
Goal 2: Morning ADLs
+4 = <5 minutes (normal)
+3 = <10 minutes
+2 = <15 minutes
+1 = <20 minutes
0 = 20 minutes
-1 = >30 minutes
Goal Attainment Scale
4
3
2
1
0
-1
BL1
BL2
wk4
wk8
Visit

FIG. 21